When: Confirmed close >$91.00 with constructive volume

Then: Final tranche toward Overweight

When: Pullback to $82-83 with confirmed capitulation (RSI <30 + bullish divergence on daily)

Then: Scale into full benchmark weight

When: Q3 FY2026 print confirms NA organic stabilization with op margin >18.5% AND reaffirms FY guidance

Then: Upgrade to Overweight at 80-85% benchmark weight

SELL (reduce exposure to 1.5-2.5% defensive weighting)

• 200 SMA reclaim at $88.02 is marginal (price sits 0.09% above MA), not a confirmed breakout signal; pattern of failed breakouts seen repeatedly over past three months
• 50 SMA capping upside at $89.23; structural downtrend from July peak at $95.46 to October low at $84.26 remains intact until close above 50 SMA
• MACD histogram positive by only 0.36 (one bar) with both lines still negative at -0.67 and -1.03; momentum improving from oversold but not a reversal signal
• Fair value at 21.5x forward P/E provides no margin of safety; multiple already assumes worst on rates with no macro tailwind
• EM FX translation drag is mechanical and persistent in higher-for-longer regime; 40% EM revenue exposure creates ongoing earnings volatility
• Buyback reduction of 30% year-over-year is a management tell signaling either full valuation, better capital uses, or liquidity concerns
• Two impairment charges in three years totaling over $1.6 billion represent a pattern, not a one-time event; $3.12B goodwill and $1.54B intangibles remain at risk
• Realistic near-term risk-reward: ~2.6% upside to $90.36 vs ~4.2% downside to $84.40; stretch case to $95.46 requires full trend reversal
• Bounce from $84.26 October low to $88.10 represents 4.6% recovery; trimming into this bounce is selling strength, not weakness
• Current 1.5-2.5% position size after trimming is appropriate for unresolved technicals and stacked macro risks

→ vs aggressive: The 200 SMA reclaim is not a clean signal; price is only 0.09% above the MA and has produced failed breakouts repeatedly over three months

→ vs aggressive: MACD histogram flip is one bar inside multi-month bearish structure; buying every MACD flip in CL over past six months would leave most entries underwater

→ vs aggressive: Fair value at 21.5x P/E provides no margin of safety; next move requires either dovish surprise or exceptional execution to expand multiple, not a tailwind

→ vs aggressive: EM FX translation drag is mechanical and persistent in higher-for-longer regime, not a buy-through opportunity

→ vs aggressive: Buyback decline signals management's own view of forward outlook or full valuation; 83% capital return ratio masks the concerning signal

→ vs aggressive: Normalized EPS of $3.48 assumes no further impairments; forward $4.10 estimate cannot underwrite absence of event that has occurred twice in three years

→ vs aggressive: Using 8.3% stretch case to $95.46 as the base case is misleading; base case is choppy consolidation between $84-$90 awaiting Q3 earnings

Partial trim to lower end of 1.5-2.5% weighting; maintain defensive exposure with defined entry and exit triggers; no additions at current levels; first add trigger is a confirmed close above $89.23 on volume

• Current price at $88.10 with immediate resistance at $88.63 (upper band); close above $88.63 on above-average volume opens path to 50 SMA test
• Lower band at $84.40 acts as hard invalidation level on remaining position
• First add trigger: confirmed close above $89.23 (only 1.3% away) on volume
• 200 SMA reclaim is thin (8-cent touch) on single session without volume confirmation; not a clean mean-reversion round-trip
• MACD improving but not confirmed; RSI neutral with room to run
• Forward P/E of 21.5x embeds real assumption set; impairments add probability-weighted drag on EPS
• Aggressive analyst's 8.3% upside to $95.46 (July peak) is stretch case, not base case; base case is $90.36 (September swing high at 2.6% away)
• Macro fully priced at 96% no-cuts probability offers no tailwind but no obvious incremental shock
• Colgate fundamentals intact: 0.32 beta, 2.43% yield, 50% global toothpaste share, $3B+ goodwill
• Buyback and impairment concerns are legitimate but not binary; they warrant conservative multiple discount, not exit
• Aggressive analyst conflates long-term business quality with short-term trade timing; patience is a feature in a 0.32 beta name
• Traders SELL label mismatches actual action (trim 40-50% of position); more coherent to label as defensive trim

→ vs aggressive: Selectively embraces weak technical signals (200 SMA reclaim) when supportive but dismisses same weakness (8-cent marginal touch) when against; confusing long-term quality with short-term timing; treats patience as cost rather than feature; uses bull case stretch target ($95.46) as median outcome

→ vs conservative: Macro argument about 96% no-cuts being bearish is inverted—if bad news is priced, asymmetry shifts; impairments are probability-weighted EPS drag, not binary exit catalyst; buyback/impairment concerns justify conservative multiple but not full position exit; tactical error in agreeing HOLD is dangerous then supporting SELL when trader is actually just trimming 40-50%